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Effects of EzetimibeTsujita et al. (1) report patients randomized to ator-
vastatin þ ezetimibe therapy experienced a greater
reduction in the percentage of atheroma volume than
those randomized to atorvastatin, and it may be due
to the lower mean low-density lipoprotein choles-
terol achieved. However, Crea and Niccoli (2) argued
and hypothesized that cholesterol lowering itself
does not seem to explain the greater reduction in the
percentage of atheroma volume with convincing and
intriguing pleiotropic effects of ezetimibe.
Statins are very important to prevent cardiovascular
events in patients at high risk, but dose-dependently
worsen insulin sensitivity and increase the risk of
type 2 diabetes (3). In addition to lowering LDL
cholesterol further, ezetimibe reduced visceral fat
with beneﬁcial effects on adiponectin and insulin
resistance. Indeed, experimental studies demon-
strated that ezetimibe improves liver steatosis and
insulin sensitivity in a rat model of metabolic syn-
drome. We observed that ezetimibe combined with
simvastatin signiﬁcantly decreased insulin levels and
increased adiponectin levels and insulin sensitivity
and reduced visceral fat and blood pressure quite
differently from simvastatin alone in patients with
hypercholesterolemia (4). Indeed, a randomized clin-
ical trial demonstrated that simvastatin combined
with ezetimibe therapy wasmore beneﬁcial in patients
with diabetes than in patients without diabetes
(p interaction ¼ 0.023) (5). These may in part explain
the results of the IMPROVE-IT (Examining Outcomes
in Subjects with Acute Coronary Syndrome: Vytorin
(Ezetimibe/Simvastatin) Versus Simvastatin (P04103)
and PRECISE-IVUS (Plaque Regression With Choles-
terol Absorption Inhibitor or Synthesis Inhibitor Eval-
uated by Intravascular Ultrasound) studies.*Kwang Kon Koh, MD, PhD
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Effects of EzetimibeWe read with great interest the letter by Dr. Koh
commenting on our recent paper (1), and we appre-
ciate his valuable comments on the possible mecha-
nisms underlying the greater coronary plaque
regression observed in patients treated with the
combination of a statin plus ezetimibe compared with
statin monotherapy. In terms of “pleiotropic” bene-
ﬁcial effects of the dual lipid-lowering pharmaco-
therapy, we completely agree with Dr. Koh. As shown
in the Central Illustration demonstrating the rela-
tionship between the achieved low-density lipopro-
tein cholesterol (LDL-C) levels and the median change
in the percentage of atheroma volume (1), the plot
was located far below the pre-existing regression line
in the atorvastatin/ezetimibe combination arm of the
acute coronary syndrome cohort of the PRECISE-IVUS
(Plaque Regression With Cholesterol Absorption In-
hibitor or Synthesis Inhibitor Evaluated by Intravas-
cular Ultrasound) trial, suggesting the presence of
“beyond LDL-C-lowering effect” of the dual lipid
lowering.
What would be the possible explanation of the
“beyond LDL-C?” Looking at Figure 4 in our PRECISE-
IVUS paper (1), coronary plaque regression was
correlated with serum levels of a cholesterol absorp-
tion marker as well as or stronger than with LDL-C.
Also, Dr. Koh mentioned that statin combined with
ezetimibe therapy was more beneﬁcial in patients
with diabetes than without diabetes. Recently, small
dense LDL-C has been highlighted as a new risk factor
for coronary heart disease, and an increased small
dense LDL-C level was found in patients with type 2
diabetes (2). Furthermore, it has been reported
that elevation of small dense LDL-C levels was
associated with insulin resistance (3) and metabolic
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gression/regression, we showed in the PRECISE-IVUS
that the atherogenic small dense LDL-C level was
signiﬁcantly suppressed in patients with plaque
regression compared with patients with plaque pro-
gression. In addition, the combination of a statin and
ezetimibe showed a greater reduction in small
dense LDL-C levels in diabetic patients compared
with higher dose statin monotherapy (5). Similar to
the consideration by Dr. Koh, these ﬁndings thus
may explain the clinical beneﬁt of a dual lipid-
lowering strategy observed in the PRECISE-IVUS and
IMPROVE-IT (Examining Outcomes in Subjects with
Acute Coronary Syndrome: Vytorin (Ezetimibe/Sim-
vastatin) studies, indicating the expected efﬁcacy in
high-risk patients such as those with diabetes, and
warrant further studies to conﬁrm these mechanis-
tical considerations.*Kenichi Tsujita, MD, PhD
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Control in Type 1 Diabetes
With Long-Term Risk
After CABGWith great interest, we read the recent article by
Nyström et al. (1) assessing the relationships of
preoperative glycemic control in type 1 diabetes and
long-term risks of major adverse cardiovascular
events (MACE) and all-cause mortality after coronary
artery bypass grafting (CABG) in an observational
cohort study. They showed that preoperative poor
glycemic control deﬁned by hemoglobin A1c levels
was associated with increased long-term risks of
MACE and all-cause mortality. The strengths of this
study include the large sample of patients with a
long follow-up and use of appropriate statistical
methods to estimate the relationships of preopera-
tive glycemic control with the risks of MACE and all-
cause mortality. In our view, however, several issues
in this study seemed not to be well addressed.
First, perioperative blood management was not
included in the study design. It has been shown that
preoperative anemia is common among patients un-
dergoing CABG and is an important risk factor for
early and late mortality after surgery (2). Further-
more, the combined mortality risk of pre-operative
anemia and perioperative transfusion is nearly triple
that of nonanemic patients not receiving transfusion.
In addition, post-operative anemia is also common,
with an incidence of 44% and frequently persists for
months after CABG. When the postoperative hemo-
globin level is considered a continuous variable,
every 1-mg/dl decrease in hemoglobin level is asso-
ciated with a 13% increase in MACE and a 22% in-
crease in all-cause mortality (3). We are concerned
that the existence of any imbalance in these factors
among patients with the different hemoglobin A1c
levels would have confounded interpretation of their
results.
Second, the variables used for adjusted hazard
ratios of MACE and long-term all-cause mortality in
the multivariable model only included the baseline
